Tocovid Suprabio (HOV-12020)

Phase 2Small molecule

Tocovid Suprabio (HOV-12020) is one of 5 small molecule programs targeting Parkinson's Disease (PD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's Disease (PD)Active, not recruiting

Parkinson's Disease (PD)Phase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Parkinson's Disease (PD)

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

TJ0113

HHangzhou PhecdaMed Co., Ltd.

Phase 3

1 3

Tocovid Suprabio (HOV-12020)

NNational Neuroscience Institute

Phase 2

1 4

AAV2-Haadc

KKrzysztof Bankiewicz

Phase 1

1 5

Buntanetap/posiphen

AAnnovis Bio Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Parkinson's Disease (PD)

NCT04491383

Clinical

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

Tocotrienols in Parkinson's Disease (PD)

Active, not recruiting·NNational Neuroscience Institute·Phase 2·NCT04491383·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tocovid Suprabio (HOV-12020). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tocovid Suprabio (HOV-12020) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tocovid Suprabio (HOV-12020). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Neuroscience Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Neuroscience Institute

Tocovid Suprabio (HOV-12020)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

References

Drug Info

Quick Facts

Related News